JNCE NASDAQ
Jounce Therapeutics, Inc.
1W: -2.6%
1M: -1.1%
3M: +55.4%
1Y: -64.0%
3Y: -64.8%
5Y: -90.7%
$1.88
Last traded 2023-05-05 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$82M
+204.8% ▲
5Y CAGR: +2.7%
Gross Profit
$82M
+204.8% ▲
5Y CAGR: +2.7%
Operating Income
-$52M
+42.6% ▲
Net Income
-$51M
+44.0% ▲
EPS (Diluted)
$-0.99
+45.6% ▲
EBITDA
-$50M
+44.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $65M | $148M | $62M | $27M | $82M |
| YoY Growth | -9.0% | +126.8% | -57.8% | -56.8% | +204.8% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $65M | $148M | $62M | $27M | $82M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $70M | $67M | $79M | $89M | $103M |
| SG&A Expenses | $26M | $28M | $29M | $29M | $31M |
| Operating Expenses | $96M | $95M | $107M | $118M | $134M |
| Operating Income | -$31M | $53M | -$45M | -$91M | -$52M |
| Operating Margin | -48.0% | 35.7% | -72.4% | -338.4% | -63.7% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$27M | $57M | -$44M | -$91M | -$51M |
| Tax Expense | $46K | $46K | $14K | $15K | $135K |
| Net Income | -$27M | $57M | -$44M | -$91M | -$51M |
| Net Margin | -42.0% | 38.4% | -70.3% | -337.7% | -62.1% |
| EPS (Diluted) | $-0.84 | $1.66 | $-1.24 | $-1.82 | $-0.99 |
| EBITDA | -$24M | $53M | -$45M | -$91M | -$50M |
| Shares Outstanding | 33M | 34M | 35M | 50M | 52M |